Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Cirevetmab Recombinant Canine Monoclonal Antibody
GREENER_CHOICE

Catalog No. MA562414
Encompass_Preferred
Change view
Click to view available options
Quantity:
100 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
MA562414 100 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. MA562414 Supplier Invitrogen™ Supplier No. MA562414
Only null left
Add to Cart
Add to Cart

Canine Recombinant Monoclonal Antibody

Cirevetmab Recombinant Monoclonal Antibody for Flow, ELISA, Functional Assay

Cirevetmab is a monoclonal antibody targeting the interleukin-13 receptor alpha 2 (IL13R alpha-2). It is being explored for the treatment of cancers that overexpress IL13R alpha-2 such as glioblastoma by delivering targeted therapy to tumor cells.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Cirevetmab
Applications ELISA, Flow Cytometry, Functional Assay
Classification Recombinant Monoclonal
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with no preservative; pH 7.4
Gene Alias CAS:2473240-98-9; ZTS00521426; ZTS-00521426
Host Species Canine
Purification Method Protein A/G
Quantity 100 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Canine
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG2 κ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.